Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patterns in Attribute Selection and Development Reporting in Patient Preference Studies Between 2007-2024: A Systematic Literature Review.

Journal of health economics and outcomes research·2026
Same author

Preference-based scoring algorithm to estimate societal utilities based on the patient-reported experience of cognitive impairment in schizophrenia (PRECIS) instrument.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation·2026
Same author

Patient Preferences and Treatment Decision Drivers in IDH-Mutant Grade 2 Glioma: An International Discrete Choice Experiment.

The patient·2026
Same author

Evaluating work activity and societal burden in patients with grade 2 IDH-mutant glioma.

Neuro-oncology practice·2026
Same author

Perspectives of Healthcare Professionals on the Treatment Landscape of Ocular Redness.

Patient preference and adherence·2026
Same author

Understanding the Humanistic Burden of Metabolic Dysfunction-Associated Steatohepatitis Liver Disease in the US Population: Age/Sex Stratified Analysis of Morbidity and Mortality.

PharmacoEconomics - open·2026

Related Experiment Video

Updated: Sep 8, 2025

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
06:27

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

Published on: May 9, 2025

560

Estimating Health State Utilities for IDH-Mutant Diffuse Glioma.

Ellen M Howard1, Marc Massetti2, Gin Nie Chua3

  • 1Acaster Lloyd Consulting Ltd, Lacon House, 84 Theobalds Rd, London, WC1X 8NL, UK. ellen.howard@acasterlloyd.com.

Pharmacoeconomics - Open
|September 6, 2025
PubMed
Summary
This summary is machine-generated.

This study estimated health state utilities for isocitrate dehydrogenase-mutant (mIDH) gliomas. New treatments delaying recurrence and the start of radio-/chemotherapy (RT/CT) may improve quality of life for patients.

More Related Videos

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections
05:45

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Published on: July 31, 2017

9.7K
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
06:32

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Published on: January 9, 2019

8.0K

Related Experiment Videos

Last Updated: Sep 8, 2025

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
06:27

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

Published on: May 9, 2025

560
Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections
05:45

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Published on: July 31, 2017

9.7K
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
06:32

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Published on: January 9, 2019

8.0K

Area of Science:

  • Neuro-oncology
  • Health Economics
  • Quality of Life Research

Background:

  • Isocitrate dehydrogenase-mutant (mIDH) gliomas are aggressive brain tumors.
  • Patients often experience recurrence requiring radio-/chemotherapy (RT/CT) after initial resection.
  • Cost-utility analyses (CUA) are crucial for evaluating treatments that delay disease progression.

Purpose of the Study:

  • To estimate health state utilities for mIDH glioma patients throughout the disease course.
  • To provide data for cost-utility analyses of novel treatments.
  • To inform decision-making regarding treatment sequencing and resource allocation.

Main Methods:

  • Developed health state vignettes based on literature, clinical trial data, and expert/patient interviews.
  • Valued health states using the EQ-5D-5L and time trade-off methods with UK public participants.
  • Re-weighted vignette utilities with clinical trial data for CUA application.

Main Results:

  • Health state utilities were highest post-initial resection (0.74) and decreased in later disease stages.
  • Mean utilities for first- and second-line RT/CT ranged from 0.34 to 0.55.
  • Utilities for recovery after recurrence ranged from 0.21 to 0.42, and palliative care from -0.05 to 0.14.

Conclusions:

  • This study provides essential health state utility values for mIDH glioma patients from post-resection to palliative care.
  • Treatments delaying disease recurrence and RT/CT initiation could significantly improve patient quality of life.
  • The findings support the development of interventions aimed at extending progression-free survival in mIDH glioma.